2025-05-07 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official…
